ArticleJournal of medicinal chemistry2024
Structure Activity of β-Amidomethyl Vinyl Sulfones as Covalent Inhibitors of
Abstract read
In one paragraph
Article in Journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Computational identification of potential inhibitors for chikungunya virus nsP2pro.Royal Society open science · 2026Article
- Development of Covalent Inhibitors of Chikungunya Virus nsP2 Cysteine Protease Enabled by Direct-to-Biology Synthesis and Screening.Journal of medicinal chemistry · 2026Article
- Recent progress in anti-Chikungunya virus drug discovery: Focus on the viral life cycle and direct-acting antivirals.Virologica Sinica · 2026Review
- Identification and characterization of novel chikungunya virus polymerase inhibitors.Journal of virology · 2026Article
- Recent advances in antiviral drugs for Chikungunya virus (CHIKV): Targets, mechanisms, and development strategies.Acta pharmaceutica Sinica. B · 2026Review
- Chikungunya in 2025: Comprehensive Insights into Virology, Diagnostics, Vaccines, and Antiviral Therapies.Viruses · 2026Review
- Inhibition of Chikungunya virus nsP2 protease in vitro by scorpion venom peptide pantinin-1.PloS one · 2026Article
- Novel computational pipeline to identify target sites for broad spectrum antiviral drugs.Antiviral research · 2026Article
- Article
- Identification of Direct-Acting nsP2 Helicase Inhibitors with Antialphaviral Activity.Journal of medicinal chemistry · 2025Article
- Species-Dependent Metabolism of a Covalent nsP2 Protease Inhibitor with In Vivo Antialphaviral Activity.Journal of medicinal chemistry · 2025Article
- A covalent chemical probe for Chikungunya nsP2 cysteine protease with antialphaviral activity and proteome-wide selectivity.Scientific reports · 2025Article
- Alphavirus nsP2: A Multifunctional Regulator of Viral Replication and Promising Target for Anti-Alphavirus Therapies.Reviews in medical virology · 2025Review
- Species Dependent Metabolism of a Covalent nsP2 Protease Inhibitor withbioRxiv : the preprint server for biology · 2025Article
- Novel peptide inhibitor for the Chikungunya virus nsP2 protease: Identification and characterization.Current research in microbial sciences · 2025Article
- A Covalent Chemical Probe forResearch square · 2024Article
- Identification of Dihydropyrazolo[1,5-Pharmaceuticals (Basel, Switzerland) · 2024Article
Corrections and comments
- Update of
Authors and funding
17 authors.
Anirban GhoshalStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Kesatebrhan Haile AsressuStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Mohammad Anwar HossainStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0001-8684-8755
Peter J BrownStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Meganathan NandakumarStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Anand ValaPiramal Discovery Solutions, Pharmaceutical Special Economic Zone, Sarkhej, Bavla Highway, Ahmedabad, Gujarat 382213, India.ORCID 0000-0002-2186-820X
Eric M MertenREADDI AViDD Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
John D SearsREADDI AViDD Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Isabella LawDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Jane E BurdickDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Noah L MoralesDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Sumera PerveenStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
Kenneth H PearceREADDI AViDD Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0001-8138-5421
Konstantin I PopovREADDI AViDD Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Nathaniel J MoormanREADDI AViDD Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Mark T HeiseREADDI AViDD Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Timothy M WillsonStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0003-4181-8223
Funding
Research Project 1: Coronavirus antiviral lead development and combination testingU19AI171292 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S, WILLSON, TIMOTHY M · 2022 to 2022
$65.5MRequest for a 500 MHz NMR console and nitrogen-cooled cryoprobeS10OD032476 · OD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LEE, ANDREW L · 2022 to 2022
$599kNIAID NIH HHS U19 AI171292NIH HHS S10 OD032476
Abstract
Despite their widespread impact on human health, there are no approved drugs for combating alphavirus infections. The heterocyclic β-aminomethyl vinyl sulfone RA-0002034 (
Indexed as
Antiviral AgentsChikungunya virusCysteine EndopeptidasesSulfonesAnimalsCysteine Proteinase InhibitorsHumansStructure-Activity RelationshipVirus ReplicationAntiviral AgentsCysteine EndopeptidasesCysteine Proteinase Inhibitorsdivinyl sulfonensP2 proteinaseSulfones
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.